FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL	. OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar O'Neill			2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI]									eck all appli Directo	cable)	ng Per	son(s) to Iss 10% Ov Other (s	wner				
(Last)	,	ERAPEUTICS, 1	(Middle)			oate of 14/20		st Trans	saction (Mo	onth/l	Day/Year)	1			below)		dical	below)	респу	
555 LONG WHARF DRIVE, 12TH FLOOR						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) NEW HA	AVEN C	T	06511												_	filed by Mo		n One Repo		
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication														
						Check	this bo	ox to indi firmative	icate that a defense co	transa nditio	ns of Rule	made pursi 10b5-1(c).	uant t See I	to a cont Instructio	ract, instructi on 10.	ion or writter	n plan t	that is intende	ed to	
		Tabl	le I - Nor	n-Deriv	ative	Sec	uritie	es Ac	quired,	Dis	osed (of, or B	ene	eficiall	y Owne	d				
1. Title of Security (Instr. 3) 2. TransDate (Month)						ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Di Code (Instr. 5)		Dispose	Securities Acquired (A sposed Of (D) (Instr. 3,		(A) or 3, 4 and	5. Amou Securitie Benefici Owned F Reporte	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or	Price	Transac (Instr. 3	tion(s)			(IIISU. 4)	
Common	Common Stock			12/14	4/2023				M		521	1 A (1)		(1)	2,802			D		
		Т	able II - I						uired, D , option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Code (Inst		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	s S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership oct (Instr. 4)	
					Code	v	(A)		Date Exercisabl		xpiration ate	Title	or Nu of	umber						
Restricted Stock Units	(1)	12/14/2023			M			521	(2)	T	(2)	Common Stock	4	521	\$0.00	4,690		D		

Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

/s/ Richard Steinhart, as

12/18/2023 Attorney-in-Fact for Vincent

O'Neill

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.